NEW YORK – The Biotechnology Industry Organization's (BIO) first-ever venture capital study, which analyzed U.S. venture investments during a 10-year period – 2004 to 2013 – turned up several positive trends such as the increasing shift toward biologics and novel drug development, but there was one set of data that gave investors pause. (See BioWorld Today, Feb. 10, 2015.)